IGC Pharma, Inc.IGCEarnings & Financial Report
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
Revenue
$204.0K
Gross Profit
$133.0K
Operating Profit
$-3.0M
Net Profit
$-5.6M
Gross Margin
65.2%
Operating Margin
-1469.6%
Net Margin
-2739.7%
YoY Growth
-38.6%
EPS
$-0.09
IGC Pharma, Inc. Q4 FY2023 Financial Summary
IGC Pharma, Inc. reported revenue of $204.0K (down 38.6% YoY) for Q4 FY2023, with a net profit of $-5.6M (down 148.5% YoY) (-2739.7% margin). Cost of goods sold was $71.0K, operating expenses totaled $3.1M.
Key Financial Metrics
| Total Revenue | $204.0K |
|---|---|
| Net Profit | $-5.6M |
| Gross Margin | 65.2% |
| Operating Margin | -1469.6% |
| Report Period | Q4 FY2023 |
IGC Pharma, Inc. Annual Revenue by Year
IGC Pharma, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $1.2M |
| 2023 | $1.2M |
| 2022 | $868.0K |
IGC Pharma, Inc. Quarterly Revenue & Net Profit History
IGC Pharma, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $191.0K | -53.6% | $-1.8M | -953.4% |
| Q2 FY2025 | $328.0K | +20.6% | $-1.6M | -487.5% |
| Q4 FY2024 | $257.0K | +26.0% | $-1.8M | -711.7% |
| Q3 FY2024 | $412.0K | +41.6% | $-1.7M | -416.7% |
| Q2 FY2024 | $272.0K | -51.0% | $-2.4M | -874.3% |
| Q1 FY2024 | $295.0K | +78.8% | $-2.9M | -978.0% |
| Q4 FY2023 | $204.0K | -38.6% | $-5.6M | -2739.7% |
| Q3 FY2023 | $291.0K | +44.1% | $-2.5M | -842.3% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $291000 | $204000 | $295000 | $272000 | $412000 | $257000 | $328000 | $191000 |
| YoY Growth | 44.1% | -38.6% | 78.8% | -51.0% | 41.6% | 26.0% | 20.6% | -53.6% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.5M | $11.3M | $9.9M | $10.6M | $10.4M | $9.1M | $7.9M | $9.7M |
| Liabilities | $2.4M | $2.2M | $2.6M | $2.7M | $3.0M | $2.8M | $1.9M | $1.7M |
| Equity | $14.1M | $9.1M | N/A | $7.9M | $7.4M | $6.3M | $6.1M | $8.1M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-1.6M | $-526000 | $-1.8M | $-996000 | $-1.4M | $-2.1M |